Clinical Trial Update: Differential Vascular and Endocrine Effects of Valsartan/Sacubitril in Heart Failure With Reduced Ejection Fraction [Phase 4]

View source ↗

Summary

Phase 4 trial update analyzing differential vascular and endocrine effects of valsartan/sacubitril in heart failure with reduced ejection fraction.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• Valsartan/Sacubitril (valsartan/sacubitril)

Snippet

Sponsor: University of Zurich | Conditions: Heart Failure | Phase 4 | Status: COMPLETED